Three chemistries, one kind of customer. Blue Jet sells the chemical stages that come before a finished product, and it sells them almost entirely to large innovator companies rather than to anyone you could buy from. In the June 2026 quarter, contrast media intermediates — the iodine chemistry that makes you visible on a CT scan — were 40% of revenue, pharma intermediates and APIs 41%, and high-intensity sweeteners, mostly saccharin, 14%. It is good at the chemistry. Operating margin was 31% in the year to March 2026 and return on capital 26.5%, with more cash than debt. It is less good at predictability: revenue for that year fell 8%. The skill is doing difficult chemistry at scale for people who will not do it themselves. The exposure is that a business with few customers has few phone calls to receive.
On what it discloses, well. What it does not disclose is the measure that matters most. Plants ran at about 70% in the June 2026 quarter, and everything produced was dispatched. Fifty-one products are commercialised — 19 in contrast media, 28 in pharma intermediates and APIs, 4 in sweeteners. Three more contrast media launches are planned for the year, and of roughly twenty development opportunities being tracked, four have progressed to programmes with visibility. The order book is described as strong and never quantified. Customer concentration is not disclosed at all, and in contract manufacturing it is the single most useful number a company can give. Its absence does not hide much: a business where one buyer''s destocking moved a segment from ₹212 crore a quarter to ₹2 crore has told you the answer without printing it. Seventy per cent utilisation with ₹1,000 crore of new capacity being built is a bet on customers it has not named.
No, and the interesting question is the opposite one. Borrowings were ₹43.7 crore at March 2026 against ₹148.9 crore of cash — net cash of ₹105 crore, and debt of three paise per rupee of equity. In July 2026 the company raised a further ₹800 crore by placing 15,810,276 shares at ₹506 with institutions. Against that sits the spending. Capital work in progress was ₹301 crore at March 2026, against a gross block of ₹316 crore — the asset base is close to doubling and none of the new part is earning yet. Vizag is budgeted at about ₹1,000 crore over three years, roughly ₹250 crore of it in the current year, and Unit 3 at Mahad has taken ₹210 crore with ₹40 crore still to come. The balance sheet is not the risk here. What it is about to be spent on is.
A year backwards, then a quarter that turned. Revenue for the year to March 2026 fell 8% to ₹947 crore and profit fell 18.8% to ₹248 crore, with operating margin down to 31.1% from 36.7%. The June 2026 quarter was ₹293 crore, 25% above the March quarter, with margin back up to 33.5%. Growth, margin and profit all moved the same way twice — down together for the year, up together for the quarter. Which of the two is the trend is the question the next two quarters answer.
It went backwards, and one customer explains most of it. Revenue for the year to March 2026 was ₹947 crore, down 8% from ₹1,030 crore. Profit fell 18.8%, to ₹248 crore from ₹305 crore. Over five years revenue has still compounded at 13.7% a year and profit at 11.8%, so the year is a break in the record rather than the record itself. The June 2026 quarter was ₹293 crore — up 25% on the March quarter, still 17.5% below the same quarter a year earlier. Within it, pharma intermediates went from ₹212 crore in June 2025 to ₹2 crore in March 2026 and back to ₹121 crore, which management attributes to one customer working down inventory and now restarting. A business this size cannot hide a single customer pausing.
Entirely on its own — there is nothing to buy with. The company has no subsidiary, no associate and no joint venture, and has given no loan, guarantee or investment under section 186. That is unusual on this site and it makes the accounts simple: one set of financial statements, no consolidation to reconcile. Growth is plants. Unit 3 at Mahad is a backward-integration project for contrast media intermediates with ₹210 crore spent and ₹40 crore to come, commissioning slightly ahead of the second-half guidance. Vizag is about 100 acres with consent to establish received and roughly ₹1,000 crore of Phase 1 spending planned over three years. An R&D centre at Hyderabad was due to open by September 2026. Contracts committed but not yet executed stood at ₹69 crore at March 2026, from ₹49 crore. Everything it will be in three years, it is building itself.
Down over the year, up over the quarter, and raw materials explain both. Operating margin was 31.1% in the year to March 2026, from 36.7%. The six-year path is 41.4%, 36.5%, 30.4%, 32.4%, 36.7%, 31.1% — this is a margin that moves several points a year in either direction, not one that trends. In the June 2026 quarter it recovered to 33.5% from 30.4%, which the company attributes to operating leverage on higher sales rather than better pricing. Gross margin went the other way, 53% against 56%, on raw material prices that have risen since March. Management expects to pass those on, "with a few quarter gap". So the margin you see is the margin of two quarters ago, whichever direction costs are moving.
Yes, and by less each year. Return on capital employed was 26.5% in the year to March 2026, from 40.6%. Going back: 59%, 52.9%, 35.5%, 28.7%, 40.6%, 26.5%. Return on equity was 18.2%, from 26.9%. Two things pull it down and only one is bad. Profit fell 18.8%, which is. And ₹301 crore of capital work in progress now sits in capital employed earning nothing at all, which is what building a plant looks like in a ratio. Twenty-six per cent on capital is a good business by most standards on this site. But ₹1,000 crore is going into Vizag over three years, and every rupee of it enters the denominator before it enters the numerator, so this number gets worse before it gets better.
Cash yes, on time no. Operating cash flow was ₹334 crore in the year to March 2026 against profit of ₹248 crore — and against ₹46 crore of operating cash the year before, which is a wild swing for a company this size. Over three years cash flow adds to ₹621 crore against ₹717 crore of profit, a ratio of 0.87. Getting paid is the slow part. Debtor days were 131 and inventory days 72, with ₹339 crore of receivables against ₹947 crore of revenue — four months of sales outstanding. Some of that is structural: on certain contracts revenue is recognised only when goods reach the customer, and ₹30 crore was sitting in transit at the end of June 2026. Profit does turn into cash here. It takes a third of a year to do it.
A father, a son, and four independent directors. Akshay Bansarilal Arora is executive chairman and, on his own, holds 62.8% of the company. His son Shiven Akshay Arora is managing director. Two further whole-time directors, Naresh Suryakant Shah and Popat Bhagwan Kedar, complete the executive side. The board at March 2026 had eight members, four executive and four independent — Girish Paman Vanvari, Divya Sameer Momaya, Priyanka Yadav and Preeti Gautam Mehta. That is the minimum independence the listing rules allow for a board chaired by an executive, and three of the four independents are women. Trust so far has been earned on the dull things: a clean audit, nothing pledged, no money flowing to the eight family-controlled entities the accounts disclose. The one thing shareholders were not consulted on was the chairman selling 6% of the company.
The audit is clean. The tax dispute is not small. KKC & Associates LLP gave an unmodified opinion on the accounts for the year to March 2026. Because there are no subsidiaries there is only one set of statements, so none of the usual gap between standalone and consolidated arises here. The dispute is with the income tax department, over depreciation claimed on goodwill for assessment years 2020-21 to 2023-24. The demand is ₹193 crore. The company had already provided ₹129 crore of tax in earlier years, paid a further ₹16.5 crore under protest during the year to obtain a stay, and carries the remaining ₹65 crore of interest as a contingent liability without providing for it, on legal advice that it has a strong case on both jurisdiction and merits. The matter is under appeal. Everything else is rounding: ₹0.4 crore of GST and customs, and an ex-employee suing for half his back wages.
It competes in three different fights, and it is small in all of them. In contrast media intermediates the customers are a handful of global imaging formulators and the field is narrow — the company expects to be among the most vertically integrated players in that chain once Mahad commissions. In pharma intermediates and APIs it is up against every Indian contract manufacturer, most of them several times its size. In sweeteners it is up against Chinese saccharin. What makes it different is that first business. Nobody else on this site derives two-fifths of revenue from medical imaging.
Of the nine contract manufacturers covered on this site, Blue Jet is the smallest and the second most profitable. Revenue of ₹947 crore compares with Shilpa Medicare at ₹1,535 crore, Neuland at ₹2,023 crore, Anthem Biosciences at ₹2,124 crore, Sai Life at ₹2,192 crore, Syngene at ₹3,739 crore, Gland Pharma at ₹6,431 crore, Laurus Labs at ₹6,813 crore, Piramal Pharma at ₹8,869 crore and Divi''s Laboratories at ₹10,560 crore. It is a tenth the size of the largest. On margin the order reverses. Its 31.1% operating margin is behind only Anthem at 39.3%, and ahead of Divi''s at 32.6%, Sai Life at 28.8%, Neuland at 28.7%, Shilpa at 28.3%, Laurus at 26.2%, Gland at 25.4%, Syngene at 24.6% and Piramal at 10.4%. Return on capital, at 26.5%, is second only to Anthem. Small, and better at converting a rupee of sales than almost anyone it is measured against.
Almost everything in its favour is in the future tense. To come: a pharma intermediates business restarting after a customer''s destocking, which management believes can hold through the year; Mahad commissioning slightly ahead of schedule; ₹800 crore raised in July; plants running at about 70%, so there is room before the new capacity is needed; three contrast media launches planned for the year and four development programmes with visibility out of roughly twenty being tracked. Working against it, all of it present tense: raw material prices rising since March, which it can pass on only with a few quarters'' delay; revenue recognised when goods arrive rather than when they ship, so container shortages move sales between quarters and ₹30 crore of it sat in transit at the end of June; and a customer base concentrated enough that one buyer pausing took a segment from ₹212 crore a quarter to ₹2 crore. The case for the company is a plan. The case against it is a shipping schedule and a phone call.
Two industries, and only the smaller one runs on the cycle everybody worries about. Most contract manufacturers live and die by Western drug development — when biotech funding dries up, molecules stop moving and revenue goes with them. That is true of Blue Jet''s pharma intermediates business, which is 41% of revenue and the half that fell from ₹212 crore in a quarter to ₹2 crore and back to ₹121 crore. Contrast media is not that industry. It follows how many CT and MRI scans get done, which follows hospital capacity, insurance coverage and how old a population is. Those move slowly and in one direction. Iodinated contrast agents are decades-old molecules with no patent cliff to fall off, and demand for them grows with imaging volumes rather than with drug pipelines. So the boom-and-bust risk is real but concentrated in the smaller half. What replaces it in the larger half is not cyclicality, it is concentration: in imaging the buyers are a handful of global formulators, and losing one of those is not a bad quarter, it is a bad decade.
About ₹11,300 crore for a company that earned ₹248 crore and shrank. At ₹596.15 on 21 August 2026, across the 189,275,701 shares in issue after July''s placement, the market is paying roughly 45 times last year''s profit. That is the cheap end of the nine contract manufacturers covered here — and it is cheap for a reason a reader can see: it is the only one of the nine whose revenue and profit both went down. Whether the price is worth paying is a question about ₹1,000 crore of plant that has not started earning.
The lowest multiple in this group belongs to the only company in it whose profit fell. The share was ₹596.15 on 21 August 2026. Across 189,275,701 shares — the count after July''s placement of 15,810,276 new shares at ₹506 — that is a market value of about ₹11,300 crore, or 45 times the ₹248 crore earned in the year to March 2026. Of the nine contract manufacturers on this site, only Gland Pharma is priced as low, also at 45. Syngene is at 52, Shilpa Medicare 66, Neuland 82, Anthem 83, Sai Life 88, Divi''s 89 and Laurus 109. Piramal has no multiple because it has no profit. It is 7.6 times the book value at March 2026, or about 5.2 times once the ₹800 crore raised in July is counted in. Cheap against a peer group that is all growing. It is the one that isn''t, which is most of the discount.
Domestic funds bought, foreign funds left, and small shareholders arrived while the price halved. Foreign institutions held 0.40% at 30 June 2026, from 2.29% fifteen months earlier — very close to a complete exit. Domestic institutions went the other way, 1.33% to 4.65%, of which mutual funds are 1.72%. Together institutions are 5.05%, up a little over two points in four quarters. The number that moved most is the count of shareholders: 78,917 at 30 June 2026 against 54,581 at 31 March 2025. Forty-five per cent more owners over a period in which the share fell by more than half. Domestic institutions bought roughly what the chairman sold. Foreign funds took the other side.
One, and only just. At 30 June 2026 a single shareholder outside the promoter group held more than 1% of the company: the ICICI Prudential Pharma, Healthcare and Diagnostics Fund, at 1.11%. It was not on the register at 31 March 2025. That is the whole list. With promoters at 79.81% and the largest outside holder at 1.11%, there is almost nothing here for a reader to follow — no well-known domestic investor, no foreign fund of any size, no strategic holder.
Raising, yes — ₹800 crore of it, and it is the first time since listing. In July 2026 the company placed 15,810,276 new shares at ₹506 each with qualified institutions, taking the count from 173,465,425 to 189,275,701. That is 9.1% dilution, and until it happened the share count had not moved in four years. The dividend is small and steady: ₹1.20 a share for the year to March 2026, about ₹21 crore, 8.4% of profit — a yield of 0.2% at ₹596.15 on 21 August 2026. There has been no buyback. Neither the dividend nor the dilution is the point. The ₹800 crore is, and Vizag is where it goes.
Loading…